SIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.
|
|
- Augustine Hines
- 6 years ago
- Views:
Transcription
1 SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride monohydrate respectively. Properties Pramipexole, the active ingredient of SIFROL, is a dopamine agonist and binds with high selectivity and specificity to the dopamine D2 subfamily receptors and has a preferential affinity to D 3 receptors; it has full intrinsic activity. SIFROL alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover. In vitro studies demonstrate that pramipexole protects neurons from levodopa neurotoxicity. In human volunteers a dose-dependent decrease in prolactin was observed. In patients SIFROL alleviates signs and symptoms of idiopathic Parkinson s disease. Controlled clinical trials included approximately 1500 patients of Hoehn and Yahr stages I IV. Out of these, approximately 900 were in more advances stages, received concomitant levodopa therapy, and suffered from motor complications. Efficacy of SIFROL in the controlled clinical trials was maintained for the duration of the trials, approximately six months. In open continuation trials lasting for more than three years there were no signs of decreasing efficacy. Indication SIFROL â tablets are indicated for treatment of the signs and symptoms of advanced idiopathic Parkinson s disease in combination with levodopa i.e. over the course of the disease, when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or on off fluctuations). Contraindications Hypersensitivity to pramipexole or any other component of the product. Side Effects Undesirable Effects The following adverse events have been reported more frequently during the use of SIFROL than under placebo: nausea, constipation, somnolence, hallucinations and insomnia. The incidence of somnolence is increased at doses higher than 1.5 mg/day (salt) (see section Posology and
2 method of administration). More frequent adverse reactions in early disease were somnolence and constipation and in advanced disease, in combination with levodopa treatment, dyskinesias and hallucinations. These adverse events decreased with continued therapy; constipation, nausea and dyskinesia tended to disappear. The incidence of hypotension under SIFROL, compared to placebo treatment, was not increased. However, in individual patients, hypotension may occur at the beginning of treatment, especially if SIFROL is titrated too fast. Insomnia and peripheral oedema have been reported. Patients treated with pramipexole tablets have reported falling asleep during activities of daily living, including the operation of motor vehicles, which sometimes resulted in accidents. Some of them did not report a warning sign such as somnolence, which is a common occurrence in patients receiving pramipexole tablets at doses above 1.5 mg (salt)/day, and which, according to the current knowledge of sleep physiology, always proceeds falling asleep. There was no clear relation to the duration of treatment. Some patients were taking other medication with potentially sedative properties. In most cases where information was available, there were no further episodes following reduction of dosage or termination of therapy. Overdose Symptoms There is no clinical experience with massive overdose. The expected adverse events should be those related to the pharmacodynamic profile of a dopamine agonist including nausea, vomiting, hyperkinesia, hallucinations, agitations and hypotensions. Therapy There is no established antidote for overdose of a dopamine agonist. If signs of central nervous system stimulation are present, a neuroleptic agent may be indicated. Management of the overdose may require general supportive measures along with gastric lavage, intravenous fluids, and electrocardiogram monitoring. Special Warnings and Precautions When prescribing SIFROL tablets in a patient with renal impairment a reduced dose is suggested in line with section Dosage and Administration. Hallucinations are known as a side effect of treatment with dopamine agonists and levodopa. Patients should be informed that (mostly visual) hallucinations can occur. Dyskinesias can occur during the initial titration of SIFROL. The incidence of initial dyskinesia may be higher in women. If they occur, the dose of levodopa should be decreased.
3 Sudden onset of sleep during daily activities has been reported in rare cases. This can be life threatening to the patient or others depending on the circumstances. These episodes have been reported in some cases without awareness of warning signs. If this occurs, reduction of dosage or termination of therapy should be considered. Patients being treated with pramipexole must be informed not to drive or engage in other activities where impaired alertness could put themselves or others at risk of serious injury or death (e.g. operating machines). Because of possible additive effects, caution should be advised when patients are taking other sedating medication or alcohol in combination with pramipexole (see Effects on Ability to Drive and Operate Machines and Undesirable Effects). Patients with psychotic disorders should only be treated with dopamine agonists if the potential benefits outweigh the risks. Ophthalmologic monitoring is recommended at regular intervals or if vision abnormalities occur. In case of severe cardiovascular disease, care should be taken. It is recommended to monitor blood pressure, especially at the beginning of treatment, due to the general risk of postural hypotension associated with dopaminergic therapy. Symptoms suggestive of a neuroleptic malignant syndrome have been reported with abrupt withdrawal of dopaminergic therapy (see Posology and Method of Administration : Treatment Discontinuation). Pregnancy and Lactation The effect on pregnancy and lactation has not been investigated in humans. Pramipexole was not teratogenic in rats and rabbits, but was embryotoxic in the rat at maternotoxic doses. SIFROL should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. As SIFROL treatment inhibits secretion of prolactine in humans inhibition of lactation is expected. The excretion of SIFROL into the breast milk has not been studied in women. In rats, the concentration of drug was higher in the breast milk than in plasma. However, if its use is unavoidable, breast-feeding should be discontinued. Effects on ability to drive and use machine Hallucinations or somnolence can occur.
4 Rare cases of sudden onset of sleep have also been reported (see Special Warnings and Precautions for Use and Undesirable Effects). These episodes can be life threatening depending on the circumstances and have been reported in some cases without awareness of warning signs. Patients being treated with pramipexole must be informed not to drive or engaged in other activities where impaired alertness could put themselves or others at risk of serious injury or death (e.g. operating machines). (See Interaciton with other medicinal products and other forms of interaction). Drug Interactions Pramipexole is bound to plasma proteins to a very low (<20%) extent and little biotransformation is seen in man. Therefore, interactions with other medication affecting plasma protein binding or elimination by biotransformation are unlikely. As anticholinergics are mainly eliminated by biotransformation, the potential for an interaction is limited, although an interaction with anticholinergics has not been investigated. Selegiline and levodopa do not influence the pharmacokinetics of pramipexole. In a small pharmacokinetic study (n=9) the overall extent of absorption or elimination of levodopa was not changed by concomitant administration of pramipexole. Levodopa absorption rate was increased in 4 of 9 healthy volunteers, all of whom were female. Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by inhibition of the cationic secretory transport system of the renal tubules. Therefore, medications that are inhibitors of this active renal elimination pathway or are eliminated by this pathway, may interact with pramipexole resulting in reduced clearance of either or both drugs. Drugs included in this category are Cimetidine, Diltiazem, Quinidine, Quinine, Ranitidine, Triamterene, Verapamil, Digoxin, Procainamide and Trimethoprim. Amantadine is also eliminated by this renal pathway. Reduction of the pramipexole dose should be considered when these drugs are administered concomitantly with SIFROL. While increasing the dose of SIFROL it is recommended that the dosage of levodopa is reduced and the dosage of other antiparkinsonian medication kept constant. Because of possible additive effects, caution should be advised when patients are taking other sedating medication or alcohol in combination with pramipexole. Dosage and Administration The tablets should be taken orally, swallowed with water, and can be taken either with or without food. The daily dosage is administered in equally divided doses 3x per day. Initial treatment: Dosages should be increased gradually from a starting-dose of mg of base (0.375 mg of salt) per day and then increased every 5-7 days. Providing patients do not experience intolerable side effects, the dosage should be titrated to achieve a maximal therapeutic effect.
5 Ascending-Dose Schedule of SIFROL Week Dosage (mg of base) Total Daily Dose (mg of base) Dosage (mg of salt) Total Daily Dose (mg of salt) 1 3x x x x x x If a further dose increase is necessary, the daily dose should be increased by 0.54 mg base (0.75 mg salt) at weekly intervals up to a maximum dose of 3.3 mg of base (4.5 mg of salt) per day. However, it should be noted that the incidence of somnolence is increased at doses higher than 1.5 mg/day (salt) (see Undesirable Effects). Maintenance treatment: The individual dose should be in the range of mg of base (0.375 mg of salt) to a maximum of 3.3 mg of base (4.5 mg of salt) per day. During dose escalation in three pivotal studies, efficacy was observed starting at a daily dose of 1.1 mg of base (1.5 mg of salt). Further dose adjustment should be done based on the clinical response and tolerability. In clinical trials approximately 5% of patients were treated at doses below 1.1 mg (1.5 mg of salt). Doses higher than 1.1 mg (1.5 mg of salt) per day can be useful in patients where reduction of the levodopa therapy is intended. It is recommended that the dosage of levodopa is reduced during both the dose escalation and the maintenance treatment with SIFROL, dependent on reactions in individual patients. Treatment discontinuation: Abrupt discontinuation dopaminergic therapy can lead to the development of a neuroleptic malignant syndrome. Therefore pramipexole should be tapered off at a rate of 0.54 mg of base (0.75 mg of salt) per day until the daily dose has been reduced to 0.54 mg of base (0.75 mg of salt). Thereafter the dose should be reduced mg of base (0.375 mg of salt) per day (see Special Warnings and Precautions for use). For potential pharmacokinetic interaction with levodopa, which may be different in men and women. (see Interactions). Dosing in patients with renal impairment: The elimination of Pramipexole is dependent on renal function. The following dosage schedule is suggested for initiation of therapy: Patients with a creatinine clearance above 50 ml/min require no reduction in daily dose. In patients with a creatinine clearance between 20 and 50 ml/min, the initial daily dose of SIFROL should be administered in two divided doses, starting at mg of base (0.125 mg of
6 salt) twice a day (0.176 mg of base/0.25 mg of salt daily). In patients with a creatinine clearance less than 20 ml/min, the daily dose of SIFROL should be administered in a single dose, starting at mg of base (0.125 mg of salt daily). If renal function declines during maintenance therapy reduce SIFROL daily dose by the same percentage as the decline in creatinine clearance, i.e. if creatinine clearance declines by 30%, then reduce SIFROL daily dose by 30%. The daily dose can be administered in two divided doses if creatinine clearance is between 20 and 50 ml/min and as a single daily dose if creatinine clearance is less than 20 ml/min. Dosing in patients with hepatic impairment: Dose adjustment in patients with hepatic failure is probably not necessary, as approx. 90% of absorbed drug is excreted through the kidneys. However, the potential influence of hepatic insufficiency on SIFROL pharmacokinetics has not been investigated. Availability Tablets mg Box contains 3 strips of 10 tablets Reg. No. Tablets 0.25 mg Box contains 3 strips of 10 tablets Reg. No. Tablets 1 mg Box contains 3 strips of 10 tablets Reg. No. Store in a safe place out of the reach of children! Sensitive to light. Store below 30 C Only on doctor s prescription. Harus dengan resep dokter Manufactured by Boehringer Ingelheim Pharma KG Ingelheim am Rhein Germany Imported by: PT Boehringer Ingelheim Indonesia Bogor, Indonesia
SIFROL Composition Properties Indication
SIFROL Boehringer Composition 1 tablet contains: 0.125, 0.25 or 1.0 mg, (S)-2- amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole dihydrochloride monohydrate equivalent to 0.088, 0.18 or 0.7 mg pramipexole
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Miramel 0.088 mg, 0.18 mg, and 0.7 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Miramel 0.088 mg tablets: One tablet contains
More informationProduct Information. Sifrol Tablets
Sifrol -DL-July 2012-01 1. NAME OF THE MEDICINAL PRODUCT Sifrol 0.25 mg tablets Sifrol 1 mg tablets צהוב=הוספת טקסט. ירוק=מחיקת טקסט. Product Information Sifrol Tablets 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets MIRAPEXIN 1.1 mg tablets
More informationPRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate)
PRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate) NAME OF THE MEDICINE Pramipexole hydrochloride monohydrate. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
More informationPramipexole hydrochloride. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
SIFROL and SIFROL ER NAME OF THE MEDICINE Pramipexole hydrochloride. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole, [C 10 H 17 N 3 S], CAS registry number
More informationPharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS:
0BCore Safety Profile Active substance: Amisulpride Pharmaceutical form(s)/strength: 50, 100, 200, 400 mg tablets P-RMS: IE/H/PSUR/0017/002 Date of FAR: 28.11.2012 Core Safety Profile [amisulpride] Formulations:
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More information(pramipexole hydrochloride monohydrate) The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
NAME OF THE MEDICINE Pramipexole hydrochloride monohydrate. SIFROL and SIFROL ER (pramipexole hydrochloride monohydrate) The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,
More informationNew data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome
New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to
More informationFarmadol. Paracetamol 10 mg/ml INFUSION SOLUTION
Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties
More informationMIRAPEXIN 0.088mg tablets; 0.18mg tablets; 0.35mg tablets; 0.7mg tablets; 1.1mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER MIRAPEXIN 0.088mg tablets; 0.18mg tablets; 0.35mg tablets; 0.7mg tablets; 1.1mg tablets PRAMIPEXOLE This leaflet is a copy of the Summary of Product Characteristics
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Pramipexole Teva 0.088 mg tablets Pramipexole Teva 0.18 mg tablets Pramipexole Teva 0.35 mg tablets Pramipexole Teva 0.7 mg
More informationMirapex (pramipexole dihydrochloride) mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg Tablets
Page 4 Mirapex (pramipexole dihydrochloride) 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg Tablets Rx only Prescribing Information DESCRIPTION MIRAPEX tablets contain pramipexole, a nonergot dopamine agonist.
More informationM0BCore Safety Profile. Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg FR/H/PSUR/0066/001 Date of FAR:
M0BCore Safety Profile Active substance: Bromazepam Pharmaceutical form(s)/strength: Tablets 6 mg P-RMS: FR/H/PSUR/0066/001 Date of FAR: 26.11.2013 4.3 Contraindications Bromazepam must not be administered
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationCIZOREST Tablets (Amisulpride)
Published on: 2 Dec 2015 CIZOREST Tablets (Amisulpride) Composition CIZOREST 50mg Tablets Each film-coated tablet contains: Amisulpride..50 mg CIZOREST 100mg Tablets Each film-coated tablet contains: Amisulpride..100
More informationPatients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment
For the attention of accredited medical writers only Patients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment Data presented at the 7
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationAUSTRALIAN PRODUCT INFORMATION APO-PRAMIPEXOLE ER (PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE ) MODIFIED RELEASE TABLET
AUSTRALIAN PRODUCT INFORMATION APO-PRAMIPEXOLE ER (PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE ) MODIFIED RELEASE TABLET 1 NAME OF THE MEDICINE Pramipexole Dihydrochloride Monohydrate 2 AND 3 QUALITATIVE AND
More informationActive ingredients: Metoclopramide Hydrochloride mg Equivalent to metoclopramide hydrochloride anhydrous mg
Name Primperan 10 mg / 2 ml Metoclopramide hydrochloride anhydrous Solution for I.M. or I.V. injection (Ampoules) Composition Each 2 ml ampoule contains: Active ingredients: Metoclopramide Hydrochloride.
More informationQualitative and Quantitative Composition
DATA SHEET KEMADRIN Tablets Procyclidine Hydrochloride 5 mg Tablets Qualitative and Quantitative Composition White, round, biconvex tablets, one face with a break line and coded KT above the break line
More informationDOSAGE FORMS AND STRENGTHS Tablets: mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, and 1.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MIRAPEX safely and effectively. See full prescribing information for MIRAPEX. MIRAPEX (pramipexole
More informationAUSTRALIAN PI SIMIPEX (pramipexole dihydrochloride monohydrate)
AUSTRALIAN PI SIMIPEX (pramipexole dihydrochloride monohydrate) 1 NAME OF THE MEDICINE Pramipexole dihydrochloride monohydrate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pramipexole dihydrochloride monohydrate
More informationDecentralised Procedure. Public Assessment Report. Pramipexol-neuraxpharm 0,26 / 0,52 / 1,05 / 1,57 / 2,1 / 2,62 / 3,15 mg Retardtabletten
Decentralised Procedure Public Assessment Report Pramipexol-neuraxpharm 0,26 / 0,52 / 1,05 / 1,57 / 2,1 / 2,62 / 3,15 mg Retardtabletten Pramipexole dihydrochloride monohydrate DE/H/4703/001-007/DC Applicant:
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationUSE IN SPECIFIC POPULATIONS Dose (mg) 2-3 hours before bedtime
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MIRAPEX safely and effectively. See full prescribing information for MIRAPEX. MIRAPEX (pramipexole
More informationPRODUCT INFORMATION SIMIPEX Tablets
PRODUCT INFORMATION SIMIPEX Tablets NAME OF THE MEDICINE: Pramipexole dihydrochloride monohydrate Chemical name: (6S)-6-N-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride monohydrate
More informationPost hoc analysis from RECOVER study examined effects of Neupro (rotigotine) on surrogate markers of mood and anhedonia in Parkinson s disease
For the attention of Accredited Medical Writers Only Post hoc analysis from RECOVER study examined effects of Neupro (rotigotine) on surrogate markers of mood and anhedonia in Parkinson s disease Brussels
More informationRotigotine provided sustained efficacy and tolerability in long term studies of early and late stage idiopathic Parkinson s disease
New data presented at the American Academy of Neurology meeting showed that Neupro (rotigotine transdermal system) improved both motor and non-motor symptoms of Parkinson s disease Analysis of RECOVER
More informationCONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MIRAPEX ER safely and effectively. See full prescribing information for MIRAPEX ER. MIRAPEX ER (pramipexole
More informationNeupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease
For the attention of accredited medical writers only Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease Detailed
More informationPackage leaflet: Information for the patient. Pramipexol Teva Pharma 2.62 mg prolonged-release tablets
Package leaflet: Information for the patient Pramipexol Teva Pharma 0.26 mg prolonged-release tablets Pramipexol Teva Pharma 0.52 mg prolonged-release tablets Pramipexol Teva Pharma 1.05 mg prolonged-release
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Parkinson s disease affects individuals globally (WHO 2006). It is the most common serious movement disorder, including speech
More informationSTARTING PATIENTS ON. AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia.
STARTING PATIENTS ON AA-CLOZAPINE is the only Canadian-made treatment indicated for the symptoms of treatment-resistant schizophrenia. Indication: AA-CLOZAPINE (clozapine) is indicated in the management
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion and scientific discussion on procedures, which have been finalised before 1 April 2001. For scientific information on procedures
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:
Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is
More informationTRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Pramipexole Accord 0.088 mg tablets Pramipexole Accord 0.18 mg tablets Pramipexole Accord 0.35 mg tablets Pramipexole Accord 0.7 mg tablets Pramipexole Accord
More informationClodronate BE/H/PSUR/001/001 October 2011 Agreed CSP
Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More information3 PHARMACEUTICAL FORM Coated tablet Round, white to off-white, sugar coated tablets, plain on both sides.
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mebeverine hydrochloride 135 mg coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each coated tablet contains 135 mg of mebeverine
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationPRAMIPEXOLE dihydrochloride tablets, for oral use Initial U.S. Approval: 1997
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Pramipexole Dihydrochloride Tablets safely and effectively. See full prescribing information for
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationBONEFOS 800 mg. Bonefos adalah obat baru yang terdaftar tahun Informasi di bawah ini merupakan informasi update tahun 2008.
Bonefos adalah obat baru yang terdaftar tahun 2007. Informasi di bawah ini merupakan informasi update tahun 2008. BONEFOS 800 mg Important information, please read carefully! Composition 1 tablet contains
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Cabergoline Teva Pharma 2 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2 mg cabergoline. Excipient with
More informationSUMMARY OF PRODUCT CHARATERISTICS HYPERIUM. I.N.N. : Rilmenidine
SUMMARY OF PRODUCT CHARATERISTICS HYPERIUM I.N.N. : Rilmenidine 1. DENOMINATION HYPERIUM 1 mg, tablets 2. COMPOSITION Rilmenidine (I.N.N.) dihydrogenphosphate.1.544 mg amount equivalent to rilmenidine
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationRECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease
For the attention of Accredited Medical Writers Only RECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease Post hoc analyses of RECOVER study suggested
More information[SIMIPEX XR] modified release tablets
[SIMIPEX XR] modified release tablets Pramipexole hydrochloride monohydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about SIMIPEX XR. It does not
More informationP-RMS: FR/H/PSUR/0036/001
Core Safety Profile Active substance: Alprazolam Pharmaceutical form(s)/strength: Tablet uncoated, sugar coated, film coated, 0.25mg Tablet uncoated, 0.4 mg Tablet uncoated, sugar coated, film coated,
More informationPackage Insert. Elkar
Package Insert Elkar Product Summary 1. Name of the medicinal product Elkar 500 mg tablets 2. Qualitative and quantitative composition Each tablet contains levocarnitine 500 mg. 3. Pharmaceutical form
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tasmar 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 100 mg tolcapone.
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Pramipexole Orion 0.26 mg prolonged-release tablets Pramipexole Orion 0.52 mg prolonged-release tablets Pramipexole Orion 1.05 mg prolonged-release tablets Pramipexole
More informationData presented at major international congress
Neupro (rotigotine transdermal system) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome Data presented at major international congress
More informationPRODUCT MONOGRAPH. Pramipexole Dihydrochloride Tablets mg, 0.5 mg, 1.0 mg and 1.5 mg pramipexole dihydrochloride monohydrate
PRODUCT MONOGRAPH Pr SANDOZ PRAMIPEXOLE Pramipexole Dihydrochloride Tablets 0.25 mg, 0.5 mg, 1.0 mg and 1.5 mg pramipexole dihydrochloride monohydrate Antiparkinsonian Agent/Dopamine Agonist Sandoz Canada
More informationEffective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go )
Effective Shared Care Agreement for the treatment of severe motor complications in people with Parkinson Disease with apomorphine (APO-go ) This shared care agreement outlines the ways in which the responsibilities
More informationNausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules.
Nausicalm Cyclizine lactate 50 mg/ml solution for injection Presentation Nausicalm solution for injection is a clear colourless solution, presented in 1 ml ampoules. Uses Actions Cyclizine is a piperazine
More informationAPOMORPHINE (Adults) Shared Care Guidelines DRUG:
Shared Care Guidelines DRUG: APOMORPHINE (Adults) Indication: Treatment of motor fluctuations in patients with Parkinson's disease which is not sufficiently controlled by oral anti-parkinson medication.
More informationPrimary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia
Primary Care Prescribing Protocol to Support the Diagnosis and Management of People with Dementia This prescribing guideline provides the necessary information and guidance to support clinicians in the
More informationRESTLESS LEGS SYNDROME
Sifrol Tablets monohydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Sifrol. It does not contain all the available information. It does not
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg. Date of FAR:
Core Safety Profile Active substance: Bisoprolol Pharmaceutical form(s)/strength: Film-coated tablets 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg and 10 mg P - RMS: FI/H/PSUR/0002/002 Date of FAR: 13.12.2011
More informationPhysiotens 0.2 mg Abbott
10-14 Physiotens 0.2 mg Abbott Film-coated tablets 0.2 mg moxonidine Physiotens 0.2 mg tablets are round, convex, light pink, film-coated tablets with the stamp «0.2» on one face. Each tablet contains
More informationpramipexole hydrochloride monohydrate
Sifrol ER extended-release tablets pramipexole hydrochloride monohydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Sifrol ER. It does not contain
More informationPATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE
SCHEDULING STATUS: S5 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: ZOXADON 0,5 mg: Each tablet contains 0,5 mg risperidone. ZOXADON 1 mg: Each tablet contains 1 mg risperidone. ZOXADON 2 mg: Each
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) NL/H/PSUR/0058/001 Date of FAR:
0BCore Safety Profile Active substance: Omeprazole Pharmaceutical form(s)/strength: Losec MUPS tablets 10, 20 mg (OTC) P-RMS: NL/H/PSUR/0058/001 Date of FAR: 13.06.2013 4.2 Posology and method of administration
More informationRevised: 09/2016 None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRAMIPEXOLE DIHYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg BE/H/PSUR/0002/002 Date of FAR:
Core Safety Profile Active substance: Clotiazepam Pharmaceutical form(s)/strength: Tablets 5 mg and 10 mg P-RMS: BE/H/PSUR/0002/002 Date of FAR: 16.06.2011 4.3 Contraindications is contraindicated
More informationWhite to off white film-coated tablets, of oblong shape marked "BNVA" on one side, and "150" on the other side.
Bonviva Ibandronic acid sodium Bisphosphonate Drugs for treatment of bone diseases (M05) PHARMACEUTICAL FORM Bonviva 150 mg film-coated tablets White to off white film-coated tablets, of oblong shape marked
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:
M0BCore Safety Profile Active substance: Zolmitriptan Pharmaceutical form(s)/strength: ordispersible tablet P-RMS: SE/H/PSUR/0022/002 Date of FAR: 15.03.2014 4.3 Contraindications Zolmitriptan is contraindicated
More informationHow it works. Use in children
contains the active ingredient pramipexole hydrochloride monohydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about PRAMIPEXOLE XR GP. It does not
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET VERGO 16 1. Product Name Vergo 16, 16 mg, tablet. 2. Qualitative and Quantitative Composition Each tablet contains 16 mg of betahistine dihydrochloride. For the full list of excipients,
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationAfter i.v injection 45% of the amount of desmopressin is found in the urine within 24 hours.
MINIRIN Tablets 0.1 and 0.2 mg Declaration Tablets 0.1 mg. Each tablet contains desmopressin acetate 0.1 mg and excipients q.s Tablets 0.2 mg. Each tablet contains desmopressin acetate 0.2 mg and excipients
More informationMISCELLANEOUS AGENTS - ALPHA-AGONISTS
Documentation A. FDA Approved Indications ADHD (Clonidine, Guanfacine) Documentation B. Non-FDA approved, commonly used psychiatric indications 1. Alcohol and opiate dependence 2. Opioid withdrawal 3.
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationSHARED CARE PRESCRIBING GUIDELINE. TOLCAPONE for the Treatment of IDIOPATHIC PARKISON S DISEASE.
WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex
More informationSwiss Summary of the Risk Management Plan (RMP) for Ongentys (opicapone) 50 mg hard capsules
Swiss Summary of the Risk Management Plan (RMP) for Ongentys (opicapone) 50 mg hard capsules Final Version 1.0 (08 June 2018) The Risk Management Plan (RMP) is a comprehensive document submitted as part
More information0BCore Safety Profile
0BCore Safety Profile Active substance: Galantamine Pharmaceutical form(s)/strength: Film-coated tabl 4 mg, 8 mg, 12 mg Prolonged-release capsules, hard, 8 mg, 16 mg, 24 mg, Oral solution 4 mg/ml P-RMS:
More informationDorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE
SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction
More informationSUMMARY OF PRODUCT CHARACTERISTICS. One film-coated tablet contains 10 mg of cetirizine dihydrochloride.
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Cetirizin STADA 10 mg, film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 10 mg of cetirizine
More informationAmantadine Extended-Release. Gocovri, Osmolex ER. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.21 Subject: Amantadine ER Page: 1 of 5 Last Review Date: June 22, 2018 Amantadine Extended-Release
More informationSifrol ER extended-release tablets
extended-release tablets monohydrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Sifrol ER. It does not contain all the available information.
More informationPackage leaflet: Information for the user. Pramipexole Bluefish 0.7 mg tablets pramipexole
Package leaflet: Information for the user Pramipexole Bluefish 0.7 mg tablets pramipexole Read all of this leaflet carefully before you start taking this medicine because it contains important information
More information